TY - JOUR
T1 - Relationship between urinary sodium excretion and serum aldosterone in patients with diabetes in the presence and absence of modifiers of the renin-angiotensin-aldosterone system
AU - Libianto, Renata
AU - Jerums, George
AU - Lam, Que
AU - Chen, Angela
AU - Baqar, Sara
AU - Pyrlis, Felicity
AU - MacIsaac, Richard J
AU - Moran, John
AU - Ekinci, Elif I.
PY - 2014
Y1 - 2014
N2 - Although low dietary salt intake has beneficial effects on BP (blood pressure), low 24hUNa (24 h urinary sodium excretion), the most accurate estimate of dietary salt intake, is associated with increased mortality in people with diabetes. In the non-diabetic population, low salt intake is associated with increased RAAS (renin-angiotensin-aldosterone system) activity. In this cross-sectional study, we examined the relationship between 24hUNa, PRA (plasma renin activity), serum aldosterone and BNP (brain natriuretic peptide) in patients with diabetes. Clinical characteristics, 24hUNa, PRA, serum aldosterone and BNP were recorded in 222 consecutive patients (77% with Type 2 diabetes) attending a diabetes clinic at a tertiary hospital. The relationship between 24hUNa, serum aldosterone, PRA, BNP, urinary potassium excretion, serum potassium, serum sodium, eGFR (estimated glomerular filtration rate), urinary albumin excretion and HbA1c (glycated haemoglobin) was examined by a multivariable regression model. Levels of 24hUNa significantly predicted serum aldosterone in a linear fashion (R2 =0.20, P=0.002). In the subgroup of patients (n=46) not taking RAAS-modifying agents, this relationship was also observed (R2 =0.10, P=0.03), and the effect of 24hUNa on serum aldosterone was found to be more pronounced than in the whole cohort (coefficient= -0.0014, compared with -0.0008). There was no demonstrable relationship between 24hUNa and PRA or BNP. Low 24hUNa is associated with increased serum aldosterone in people with diabetes, in the presence and absence of RAAS-modifying agents. This raises the possibility that stimulation of the RAAS may be a mechanism that contributes to adverse outcomes observed in patients with low 24hUNa.
AB - Although low dietary salt intake has beneficial effects on BP (blood pressure), low 24hUNa (24 h urinary sodium excretion), the most accurate estimate of dietary salt intake, is associated with increased mortality in people with diabetes. In the non-diabetic population, low salt intake is associated with increased RAAS (renin-angiotensin-aldosterone system) activity. In this cross-sectional study, we examined the relationship between 24hUNa, PRA (plasma renin activity), serum aldosterone and BNP (brain natriuretic peptide) in patients with diabetes. Clinical characteristics, 24hUNa, PRA, serum aldosterone and BNP were recorded in 222 consecutive patients (77% with Type 2 diabetes) attending a diabetes clinic at a tertiary hospital. The relationship between 24hUNa, serum aldosterone, PRA, BNP, urinary potassium excretion, serum potassium, serum sodium, eGFR (estimated glomerular filtration rate), urinary albumin excretion and HbA1c (glycated haemoglobin) was examined by a multivariable regression model. Levels of 24hUNa significantly predicted serum aldosterone in a linear fashion (R2 =0.20, P=0.002). In the subgroup of patients (n=46) not taking RAAS-modifying agents, this relationship was also observed (R2 =0.10, P=0.03), and the effect of 24hUNa on serum aldosterone was found to be more pronounced than in the whole cohort (coefficient= -0.0014, compared with -0.0008). There was no demonstrable relationship between 24hUNa and PRA or BNP. Low 24hUNa is associated with increased serum aldosterone in people with diabetes, in the presence and absence of RAAS-modifying agents. This raises the possibility that stimulation of the RAAS may be a mechanism that contributes to adverse outcomes observed in patients with low 24hUNa.
KW - 2,4 thiazolidinedione derivative
KW - albumin
KW - aldosterone
KW - angiotensin 1 receptor antagonist
KW - antihypertensive agent
KW - beta adrenergic receptor blocking agent
KW - brain natriuretic peptide
KW - calcium channel blocking agent
KW - dipeptidyl carboxypeptidase inhibitor
KW - dipeptidyl peptidase IV inhibitor
KW - diuretic agent
KW - exendin 4
KW - ezetimibe
KW - fibric acid derivative
KW - glycosylated hemoglobin
KW - hemoglobin A1c
KW - hydroxymethylglutaryl coenzyme A reductase inhibitor
KW - insulin
KW - metformin
KW - potassium
KW - renin
KW - sodium
KW - sulfonylurea
KW - adult
KW - aged
KW - aldosterone blood level
KW - antihypertensive therapy
KW - article
KW - blood sampling
KW - clinical feature
KW - controlled study
KW - cross-sectional study
KW - diabetic patient
KW - diuretic therapy
KW - estimated glomerular filtration rate
KW - female
KW - glomerulus filtration rate
KW - hemoglobin blood level
KW - human
KW - hypertension
KW - insulin dependent diabetes mellitus
KW - insulin treatment
KW - major clinical study
KW - male
KW - multicenter study
KW - non insulin dependent diabetes mellitus
KW - plasma renin activity
KW - potassium blood level
KW - potassium excretion
KW - potassium urine level
KW - priority journal
KW - renin angiotensin aldosterone system
KW - risk factor
KW - serum
KW - sodium blood level
KW - sodium urine level
KW - tertiary health care
KW - urinalysis
KW - Aged
KW - Aldosterone
KW - Angiotensin II Type 1 Receptor Blockers
KW - Angiotensin-Converting Enzyme Inhibitors
KW - Cross-Sectional Studies
KW - Diabetes Mellitus, Type 1
KW - Diabetes Mellitus, Type 2
KW - Diuretics
KW - Female
KW - Humans
KW - Male
KW - Middle Aged
KW - Natriuretic Peptide, Brain
KW - Renin
KW - Renin-Angiotensin System
KW - Sodium
UR - http://www.scopus.com/inward/record.url?scp=84885081716&partnerID=8YFLogxK
U2 - 10.1042/CS20130128
DO - 10.1042/CS20130128
M3 - Article
C2 - 23875766
SN - 0143-5221
VL - 126
SP - 147
EP - 154
JO - Clinical Science
JF - Clinical Science
IS - 2
ER -